Literature DB >> 1583324

Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains.

P H Hoeger1, W Lenz, A Boutonnier, J M Fournier.   

Abstract

Staphylococcal skin colonization is a common feature of atopic dermatitis (AD) in adults. Little is known about prevalence and persistence of staphylococci in children. Forty-one AD children (mean age, 70 months) and 41 age-matched controls were studied. S. aureus was isolated from 38 AD patients (93%; 32% of controls, P less than .001) and 37% of AD patients (5% of controls, P less than .001) harbored toxigenic (enterotoxins, toxic shock syndrome toxin) S. aureus strains. No individual biotype prevailed. On follow-up (mean interval, 9 months), 70% of S. aureus strains were reisolated. Nasal and cutaneous S. aureus strains were identical in 73% of AD patients (7% of controls, P less than .001), reflecting increased self-contamination. Identical staphylococcal strains in AD children and their mothers were observed in 38% (S. aureus) and 16% (coagulase-negative strains; P less than .001). The prevalence of staphylococcal colonization in AD children is comparable to that in adults. High rates of self-contamination, transmission to contacts, and prevalence of toxigenic strains in AD children may have clinical and epidemiologic implications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583324     DOI: 10.1093/infdis/165.6.1064

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Association of staphylococcal superantigen-specific immunoglobulin e with mild and moderate atopic dermatitis.

Authors:  Peck Y Ong; Mona Patel; Ronald M Ferdman; Theresa Dunaway; Joseph A Church
Journal:  J Pediatr       Date:  2008-07-14       Impact factor: 4.406

2.  Pattern of bacterial colonization of atopic dermatitis in saudi children.

Authors:  Jalal Ali Bilal; Mohammad Issa Ahmad; Ahmad A Al Robaee; Abdullateef A Alzolibani; Hani A Al Shobaili; Mohammed Saleh Al-Khowailed
Journal:  J Clin Diagn Res       Date:  2013-09-10

3.  Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance.

Authors:  Kati Seidl; Martin Stucki; Martin Ruegg; Christiane Goerke; Christiane Wolz; Llinos Harris; Brigitte Berger-Bächi; Markus Bischoff
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Ventriculosubgaleal shunt in the management of recurrent ventriculoperitoneal shunt infection.

Authors:  P Steinbok; D D Cochrane
Journal:  Childs Nerv Syst       Date:  1994-11       Impact factor: 1.475

5.  Intracellular interferon-gamma (IFN-gamma) production in normal children and children with atopic dermatitis.

Authors:  D E Campbell; A S Fryga; S Bol; A S Kemp
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

6.  Production of antibodies to staphylococcal superantigens in atopic dermatitis.

Authors:  D E Campbell; A S Kemp
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

7.  Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).

Authors:  Preston Howard Blomquist
Journal:  Trans Am Ophthalmol Soc       Date:  2006

8.  Molecular architecture of the regulatory Locus sae of Staphylococcus aureus and its impact on expression of virulence factors.

Authors:  Andrea Steinhuber; Christiane Goerke; Manfred G Bayer; Gerd Döring; Christiane Wolz
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

Review 9.  Role of bacterial pathogens in atopic dermatitis.

Authors:  Yu-Tsan Lin; Chen-Ti Wang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

10.  Reduced interferon-gamma (IFN-gamma) secretion with increased IFN-gamma mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect.

Authors:  M L Tang; G Varigos; A S Kemp
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.